Scarica l'app Stockscreener
3.74
0.53%
-0.02
Dopo l'orario di chiusura:
3.73
-0.01
-0.27%
Precedente Chiudi:
$3.76
Aprire:
$3.78
Volume 24 ore:
71,827
Relative Volume:
0.15
Capitalizzazione di mercato:
$38.11M
Reddito:
-
Utile/perdita netta:
$-23.87M
Rapporto P/E:
-0.1901
EPS:
-19.67
Flusso di cassa netto:
$-47.63M
1 W Prestazione:
-1.58%
1M Prestazione:
+4.47%
6M Prestazione:
+15.43%
1 anno Prestazione:
+7.16%
Intervallo 1D:
$3.72
$3.8529
Intervallo di 1 settimana:
$3.585
$3.91
Portata 52W:
$2.30
$4.42
Polypid Ltd Stock (PYPD) Company Profile
Confronta PYPD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.74 | 38.32M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-05 | Iniziato | Roth Capital | Buy |
| 2025-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-09-14 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-07-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Iniziato | Alliance Global Partners | Buy |
| 2020-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2020-07-21 | Iniziato | Barclays | Overweight |
| 2020-07-21 | Iniziato | Raymond James | Outperform |
Mostra tutto
Polypid Ltd Borsa (PYPD) Ultime notizie
Is PolyPid Ltd. a good long term investmentExceptional earning trajectories - PrintWeekIndia
Will PolyPid Ltd. stock benefit from interest rate changesBreakout portfolio performance - jammulinksnews.com
Is PolyPid Ltd. stock a good hedge against inflationDynamic profit expansion - jammulinksnews.com
PolyPid Ltd. Stock Analysis and ForecastConsistently exceptional gains - Autocar Professional
What analysts say about PolyPid Ltd. stockUnmatched profit growth - jammulinksnews.com
What drives PolyPid Ltd. stock priceConsistent high-yield stocks - Autocar Professional
PolyPid Launches Long-Acting GLP-1 Delivery Platform for Diabetes Market - The Globe and Mail
PYPD: Positive Topline Data From D-PLEX₁₀₀ Trial Contributes to Multiple Subsequent Benefits - Yahoo Finance
PolyPid's Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market - openPR.com
How PolyPid Ltd. stock performs during market volatilityFree Exclusive Stock Market Insights - Newser
What makes PolyPid Ltd. stock price move sharplyFree Exclusive Stock Market Insights - Newser
Analysts Set PolyPid Ltd. (NASDAQ:PYPD) Price Target at $11.80 - Defense World
Finance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech - The Manila Times
PolyPid unveils 60-day GLP-1 delivery platform for diabetes treatment - Investing.com Australia
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists - GlobeNewswire
Revolutionary 60-Day GLP-1 Injection Could Replace Weekly Diabetes Treatments, PolyPid Announces - Stock Titan
Why PolyPid Ltd. stock attracts strong analyst attentionReliable Low Risk Signals - Newser
PolyPid (NASDAQ:PYPD) Raised to “Hold” at Wall Street Zen - Defense World
PolyPid (NASDAQ:PYPD) Stock Price Down 0.6% – Here’s What Happened - Defense World
Is PolyPid Stock Undervalued? (NASDAQ: PYPD) - newsblaze.com
PolyPid Announces $26.7 Million Warrant Inducement Transaction - Global Legal Chronicle
PolyPid Approves Key Resolutions at Annual Shareholder Meeting - TipRanks
Brokerages Set PolyPid Ltd. (NASDAQ:PYPD) PT at $11.25 - Defense World
PolyPid (NASDAQ:PYPD) Given a $9.00 Price Target by Roth Capital Analysts - Defense World
Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating - MarketScreener
Roth Capital Adjusts PolyPid (PYPD) Price Target Amid New Financing | PYPD Stock News - GuruFocus
PolyPid (NASDAQ:PYPD) Given New $14.00 Price Target at JMP Securities - Defense World
PYPD: JMP Securities Lowers Price Target While Maintaining Marke - GuruFocus
PolyPid (PYPD) Price Target Adjusted Amid Financing Developments - GuruFocus
PolyPid stock price target lowered to $14 at JMP on warrant dilution By Investing.com - Investing.com South Africa
Polypid Ltd Azioni (PYPD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):